



Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

-- TAC-001, Tallac's lead immunostimulatory ADC program, potentiates cancer vaccine efficacy and rejuvenates immune responses in preclinical studies --

BURLINGAME, California, April 10, 2024 (BUSINESS WIRE) --Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses. TAC-001 is an investigational, systemically delivered, Toll-like Receptor Agonist Antibody Conjugate (TRAAC) molecule, designed to selectively activate B cells to drive an anti-tumor immune response. The data will be presented today as part of the Vaccines, Antigens, and Antigen Presentation 2 session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taking place in San Diego, April 5-10, 2024.

The findings presented in the poster “A B cell targeted TLR9 Agonist Antibody Conjugate Potentiates Cancer Vaccine Efficacy and Rejuvenates Vaccine Responses in the Elderly” demonstrate that in combination with cancer vaccines, TAC-001 promotes robust and durable vaccine specific IgG titers, skews humoral response to Th1 phenotype, and rejuvenates vaccine responses. Moreover, TAC-001 enhances vaccine specific T cell activation and cytotoxic activity. As a result, anti-tumor vaccine efficacy is greatly improved by the combination with TAC-001. “The emerging data on TAC-001 in combination with cancer vaccines enhances our understanding of TAC-001 mechanisms in eliciting humoral and cellular anti-tumor immunity and provide a compelling rationale for combining TAC-001 with cancer vaccines in the clinic. This preclinical proof of concept expands the prospective therapeutic application of TAC-001 in oncology and other disease indications” said Dr. Hong I. Wan, president, CEO, and co-founder of Tallac Therapeutics.

AACR Poster Presentation Details:

- Title: “A B cell targeted TLR9 Agonist Antibody Conjugate Potentiates Cancer Vaccine Efficacy and Rejuvenates Vaccine Responses in the Elderly.”
- Session Type: Poster Session
- Session Category: Immunology
- Session Title: Vaccines, Antigens, and Antigen Presentation 2
- Abstract Number: 6746
- Section 4, April 10, 9:00AM-12:30PM

About TAC-001 (CD22 TRAAC)

TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22, a receptor restricted to B cells, including tumor-infiltrating B cells. TAC-001 is designed to systemically deliver T-CpG to B cells by binding to CD22, leading to internalization of TAC-001, TLR9 signaling, B cell activation and a cascade of immune reactions. [Preclinical studies](#) demonstrate that the innate and adaptive immune responses



triggered by TAC-001 lead to potent anti-tumor activity. TAC-001 is being developed for the treatment of solid tumors and is currently in a Phase 1/2 Study in cancer patients ([NCT05399654](#)). Emerging clinical data demonstrating tolerability, pharmacodynamic activity and preliminary clinical activity of single agent TAC-001 were observed ([SITC 2023](#)).

About Tallac Therapeutics, Inc.

Tallac Therapeutics is a privately held clinical stage biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer using next generation ADCs. Tallac's pipeline of immunostimulatory ADC candidates is derived from the company's novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and development. TAC-001, the company's lead clinical candidate, is currently in an ongoing Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. For more information, please visit www.tallactherapeutics.com.

Tallac Contact:

Curtis Hecht, CBO

650.651.3559

checht@tallactx.com